EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico—SMART 2017–2021

James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, Thales Polis, Jose L Vallejo, Katherine Young, Mary R Motyl, Daniel F Sahm

JAC-Antimicrobial Resistance · 06.05.2024 · 6 (3)

DOI: 10.1093/jacamr/dlae077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 24.05.2024. Verfasst von James A Karlowsky und 7 weiteren Autor:innen. Beteiligte Einrichtung: IHMA, 2122 Palmer Drive, Schaumburg, IL 60173, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the activities of ceftolozane/tazobactam and imipenem/relebactam against Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa isolated from hospitalized patients in Mexico in 2017–2021.

Methods

MICs were determined by CLSI broth microdilution and interpreted using CLSI M100 breakpoints. β-Lactamase genes were identified in ceftolozane/tazobactam-, imipenem/relebactam-, and/or imipenem-non-susceptible isolates.

Results

Ceftolozane/tazobactam and imipenem/relebactam inhibited 89% and 99% of E. coli isolates (n = 2337), and 87% and 94% of K. pneumoniae isolates (n = 1127). Sixty-four percent of E. coli and 47% of K. pneumoniae had an ESBL non-carbapenem-resistant Enterobacterales (ESBL non-CRE) phenotype. Eighty-six percent and 91% of ESBL non-CRE E. coli and K. pneumoniae were ceftolozane/tazobactam susceptible, and 99.9% and 99.8% were imipenem/relebactam susceptible. Ceftolozane/tazobactam was the most active agent studied against P. aeruginosa (n = 1068; 83% susceptible), 9–28 percentage points higher than carbapenems and comparator β-lactams excluding imipenem/relebactam (78% susceptible). Ceftolozane/tazobactam remained active against 35%–58%, and imipenem/relebactam against 32%–42%, of P. aeruginosa in meropenem-, piperacillin/tazobactam-, and cefepime-non-susceptible subsets. The majority of isolates of ceftolozane/tazobactam-non-susceptible E. coli carried an ESBL, whereas among ceftolozane/tazobactam-non-susceptible K. pneumoniae and P. aeruginosa, the majority carried carbapenemases. The most prevalent carbapenemase observed among E. coli (estimated at 0.7% of all isolates), K. pneumoniae (4.8%) and P. aeruginosa (10.0%) was an MBL. Almost all imipenem/relebactam-non-susceptible E. coli and K. pneumoniae carried MBL or OXA-48-like carbapenemases, whereas among imipenem/relebactam-non-susceptible P. aeruginosa, 56% carried MBL or GES carbapenemases.

Conclusions

Ceftolozane/tazobactam and imipenem/relebactam may provide treatment options for patients infected with β-lactam-non-susceptible Gram-negative bacilli, excluding isolates carrying an MBL- or OXA-48-like carbapenemase.

Autor:innen und Institutionen

  • IHMA, 2122 Palmer Drive, Schaumburg, IL 60173, USA.
  • Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Room 543-745 Bannatyne Avenue, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
  • Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA.
  • MSD Brasil, Av. Chucri Zaidan, 296-Vila Cordeiro, São Paulo 04583-110, Brazil.
  • MSD Mexico, Av. San Jerónimo 369, Tizapán San Ángel, Tizapán, Álvaro Obregón, 01090 Mexico City, Mexico.

Zitieren

APA

Karlowsky, J. A., Lob, S. H., Siddiqui, F., Polis, T., Vallejo, J. L., Young, K., Motyl, M. R., & Sahm, D. F. (2024). Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico—SMART 2017–2021. JAC-Antimicrobial Resistance, 6(3). https://doi.org/10.1093/jacamr/dlae077

Vancouver

Karlowsky JA, Lob SH, Siddiqui F, Polis T, Vallejo JL, Young K, et al. Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico—SMART 2017–2021. JAC-Antimicrobial Resistance. 2024;6(3). doi:10.1093/jacamr/dlae077

BibTeX
@article{Karlowsky2024,
  author = {Karlowsky, James A and Lob, Sibylle H and Siddiqui, Fakhar and Polis, Thales and Vallejo, Jose L and Young, Katherine and Motyl, Mary R and Sahm, Daniel F},
  title = {Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico—SMART 2017–2021},
  journal = {JAC-Antimicrobial Resistance},
  year = {2024},
  volume = {6},
  number = {3},
  doi = {10.1093/jacamr/dlae077}
}
Kostenlos starten →